natgillin/translations-raw huggingface dataset:
LÆGEMIDLETS NAVN MabThera 1600 mg opløsning til subkutan injektion
NAME OF THE MEDICINAL PRODUCT MabThera 1600 mg solution for subcutaneous injection
Klinisk erfaring med MabThera koncentrat til opløsning til infusion ved kronisk lymfatisk leukæmi
Clinical experience of MabThera concentrate for solution for infusion in CLL
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med rituximab i alle undergrupper af den pædiatriske population med kronisk lymfatisk leukæmi.
The European Medicines Agency has waived the obligation to submit the results of studies with rituximab in all subsets of the paediatric population with follicular lymphoma.
LÆGEMIDLETS NAVN MabThera 1400 mg opløsning til subkutan injektion
NAME OF THE MEDICINAL PRODUCT MabThera 1400 mg solution for subcutaneous injection
MabThera 1400 mg opløsning til subkutan injektion, indeholder:
What MabThera 1400 mg solution for subcutaneous injection contains
kemoterapi, bidrog til den relativt ringe variation i V1 (27,1 % og 19,0 %).
This variability in V1 (27.1% and 19.0%) contributed by the range in BSA (1.53 to 2.32 m2) and concurrent CHOP therapy, respectively, were relatively small.
Progressionsfri overlevelseb
Progression-free survival (PFS) Overall survival
De farmakokinetiske parametre hos patienter i populationen, der responderer utilstrækkeligt på antiTNF-behandling, var efter den samme dosis (2 x 1.000 mg, i.v.
The pharmacokinetic (PK) parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 x 1000 mg, IV, 2 weeks apart), were similar with a mean maximum serum concentration of 369 µg/mL and a mean terminal half-life of 19.2 days.
Ikke almindelig Sjælden
Very Rare
Luftveje, thorax og mediastinum bronkospasmer4, luftvejssygdomme, brystsmerter, dyspnø, øget hoste, rhinitis astma, bronchiolitis obliterans, lungesygdomme, hypoksi lungesygdom7 respirationssvigt4
Bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia lung disease7 respiratory failure4,
Tabel 2 Opsummering af bivirkningsreaktioner hos patienter med reumatoid artrit, som fik MabThera i kliniske studier eller i forbindelse med post-marketing overvågning.
Table 2 Summary of adverse drug reactions reported in clinical trials or during postmarketing surveillance occurring in patients with rheumatoid arthritis receiving MabThera
MabThera-vedligeholdelsesbehandling bestod af en enkelt MabThera-infusion på 375 mg/m2 legemsoverfladeareal hver 2. måned indtil sygdomsprogression eller i maksimalt 2 år.
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years.
• lavt immunforsvar, fordi indholdet af antistoffer i blodet, som beskytter mod infektion,
• lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG) in the blood which help protect against infection
MabThera-vedligeholdelsesbehandling bestod af en enkelt infusion med MabThera på 375 mg/m2 legemsoverflade administreret hver 3. måned indtil sygdomsprogression eller i en periode på højst 2 år.
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
Tilfælde af hepatitis B-reaktivering, herunder tilfælde af fulminant hepatitis med dødelig udgang, er blevet rapporteret hos patienter, der har fået MabThera.
Cases of hepatitis B reactivation have been reported in subjects receiving MabThera including fulminant hepatitis with fatal outcome.
Efter hver infusion steg den gennemsnitlige Cmax, fra et gennemsnit på 243 µg/ml (spændvidde 16-582 µg/ml) efter den første infusion til 550 µg/ml (spændvidde 171 - 1177 µg/ml) efter den ottende infusion.
Upon administration of MabThera at a dose of 375 mg/m2 as an intravenous infusion at weekly intervals for 8 doses to 37 patients with NHL, the mean Cmax increased with each successive infusion, spanning from a mean of 243 µg/mL (range, 16 - 582 µg/mL) after the first infusion to 550 µg/mL (range, 171 - 1177 µg/mL) after the eighth infusion.
MabThera 1600 mg opløsning til subkutan injektion, indeholder:
What MabThera 1600 mg solution for subcutaneous injection contains
Hyppigheden af bivirkninger, uanset sværhedsgrad, og hyppigheden af grad 3 og 4 bivirkninger var ens hos ældre sammenlignet med yngre (< 65 år) patienter.
The incidence of ADRs of all grades and grade 3/4 ADR was similar in elderly patients compared to younger patients (<65 years).
Hos patienter med reumatoid artrit, GPA eller MPA i sygdomsremission eller PV, bør præmedicinering i form af 100 mg methylprednisolon i.v.
In patients with rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis in disease remision or pemphigus vulgaris, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to MabThera infusions to decrease the incidence and severity of infusion related reactions (IRRs).
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) MabThera 1600 mg, opløsning til subkutan injektion Rituximab
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 1600 mg solution for subcutaneous injection Rituximab subcutaneous
Reaktioner ved indsprøjtningsstedet
Reactions where the medicine is injected
Fire doser på 375 mg/m2 MabThera blev givet som intravenøs infusion med ugentlige intervaller til
MabThera, administered as an intravenous infusion at a dose of 375 mg/m2 at weekly intervals for 4
I kombination med fludarabin og cyclophosphamid blev MabThera givet til CLL-patienter som en intravenøs infusion i en dosis på 375 mg/m2 ved første behandlingsserie og øget til en dosis på 500 mg/m2 for hver af de 5 efterfølgende behandlingsserier.
MabThera was administered as an intravenous infusion at a first-cycle dose of 375 mg/m2 increased to 500 mg/m2 each cycle for 5 doses in combination with fludarabine and cyclophosphamide in CLL patients.
Almene symptomer og reaktioner på administrations-stedet Udmattelse
General disorders and administration site conditions
Tabel 3 Bivirkninger opstået hos ≥ 5 % af patienterne i behandling med MabThera for induktion af remission af granulomatose med polyangiitis (Wegeners granulomatose) og mikroskopisk polyangiitis, og med en højere frekvens end sammenligningsgruppen, ved måned 6.
Table 3 Adverse drug reactions occurring at 6-months in ≥ 5% of patients receiving MabThera for induction of remission of GPA and MPA, and at a higher frequency than the comparator group.
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) MabThera 1400 mg, opløsning til subkutan injektion Rituximab
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION MabThera 1400 mg solution for subcutaneous injection Rituximab subcutaneous
Induktionsbehandling, 1 dosis ugentligt til i alt 8 doser I et enkelt-arms multicenterstudie fik 37 patienter med recidiveret elle kemoterapi-resistent lavmalignt eller follikulært B-celle NHL 375 mg/m2 MabThera som intravenøs infusion ugentligt i otte doser.
In a multi-centre, single-arm trial, 37 patients with relapsed or chemoresistant, low grade or follicular B cell NHL received 375 mg/m2 of MabThera as intravenous infusion weekly for eight doses.
Informationen i pkt.
body surface area.
Der er beskrevet symptomer på infusionsrelateret reaktion hos mere end 50 % af patienterne i de kliniske studier med MabThera intravenøs formulering.
Signs and symptoms suggestive of an infusion-related reaction were reported in more than 50 % of patients in clinical trials involving MabThera intravenous formulation, and were predominantly seen during the first infusion, usually in the first one to two hours.
(generelt ødem, bronkospasme, hiven efter vejret, larynxødem angioødem, generaliseret kløe, anafylaksi, anafylaktoide reaktioner)
3Infusion related reactions (generalized oedema, bronchospasm, wheezing, laryngeal oedema, angioneurotic oedema, generalized pruritus, anaphylaxis, anaphylactoid reaction)
i Studie BP22333 (3736 prøver fra 277 patienter) og Studie BO22334 (2267 prøver fra126 patienter).
The estimated median terminal elimination half-life of MabThera subcutaneous formulation was 29.7 days (range, 9.9 to 91.2 days).The analysis data set contained 6003 quantifiable samples from 403 patients administered SC and/or IV rituximab in trials BP22333 (3736 samples from 277 patients) and BO22334 (2267 samples from126 patients).
LÆGEMIDLETS NAVN MabThera 1400 mg, opløsning til subkutan injektion Rituximab
NAME OF THE MEDICINAL PRODUCT MabThera 1400 mg solution for subcutaneous injection Rituximab
LÆGEMIDLETS NAVN MabThera 1600 mg, opløsning til subkutan injektion Rituximab
NAME OF THE MEDICINAL PRODUCT MabThera 1600 mg solution for subcutaneous injection Rituximab
serumsygelignende reaktion
Cardiovascular adverse reactions
Selvom MabThera ikke er myelosuppressivt ved monoterapi, bør forsigtighed udvises, når det overvejes at behandle patienter med neutrofiltal på < 1,5 x 109/l og/eller trombocyttal på < 75 x 109/l, fordi de kliniske erfaringer hos denne population er begrænsede.
Although MabThera is not myelosuppressive in monotherapy, caution should be exercised when considering treatment of patients with neutrophils < 1.5 x 10
Urticaria
collapse
Der er efter markedsføring af MabThera intravenøs formulering rapporteret meget sjældne tilfælde af PML hos patienter med NHL (se pkt.
Very rare cases of PML have been reported during post-marketing use of the MabThera intravenous formulation in NHL (see section 4.8).
Ud over de bivirkninger, som er set i kliniske studier af RA med MabThera, er progressiv multifokal leukoencefalopati (PML) (se pkt.
In addition to adverse reactions seen in RA clinical trials for MabThera, progressive multifocal leukoencephalopathy (PML) (see section 4.4) and serum sickness-like reaction have been reported during post marketing experience.
Hvis disse reaktioner er alvorlige, kan lægen vælge at stoppe behandlingen med MabThera.
Your doctor may decide to stop your MabThera treatment if these reactions are serious.
MabThera-infusionen blev indgivet efter administration af en intravenøs infusion af 100 mg methylprednisolon.
MabThera infusions were administered after an intravenous infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisone for 15 days.
I SAWYER studiet (BO25341), rapporteredes svære administrationsrelaterede reaktioner (grad ≥3)
In SAWYER (BO25341), severe administration-related reactions (Grade ≥3) were reported in four patients (5%) following MabThera subcutaneous administration.
Effektparametre
Possible side effects
12 timer, inden du får MabThera.
You may be asked not to take these other medicines 12 hours before you are given MabThera.
ACR20 ACR50 ACR70
ACR50 (%)
Som minimum bør dette inkludere HBsAg-status og HBcAb-status.
At minimum this should include HBsAg-status and HBcAb-status.These can be complemented with other appropriate markers as per local guidelines.
alopeci urticaria, svedtendens, nattesved, +hudsygdom me svære bulløse hudreaktioner, StevensJohnsons syndrom, toksisk epidermal nekrolyse (Lyells syndrom)7
Skin and subcutaneous tissue disorders pruritis, rash, +alopecia urticaria, sweating, night sweats, +skin disorder severe bullous skin reactions, Stevens-Johns on Syndrome toxic epidermal necrolysis (Lyell's Syndrome) 7
Kvinder i den fertile alder skal anvende sikker prævention under behandlingen og i 12 måneder efter behandlingen med MabThera på grund af den lange retentionstid for rituximab hos B-celledepleterede patienter.
Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential must employ effective contraceptive methods during and for 12 months after treatment with MabThera.
De hyppigst beskrevne eller observerede alvorlige bivirkninger var: Infusionsrelaterede reaktioner (herunder cytokinfrigivelsessyndrom, tumorlysesyndrom), se pkt.
• Infusion-related reactions (including cytokine-release syndrome, tumour-lysis syndrome), see section 4.4.
Tilfælde af progressiv multifokal leukoencefalopati med dødelig udgang er rapporteret efter anvendelse af MabThera i forbindelse med behandling for autoimmune sygdomme, som inkluderer reumatoid artrit og ikke-godkendte indikationer som systemisk lupus erythematosus (SLE) og vaskulitis.
This includes rheumatoid arthritis and off-label autoimmune diseases, including Systemic Lupus Erythematosus (SLE) and vasculitis.
Intravenøs infusion
Intravenous infusion administration
Herefter anvendes
How it is given
Hvis du behandles for non-Hodgkin-lymfom Hvis du får MabThera alene
• If you are having MabThera alone
MabThera 500 mg, koncentrat til infusionsvæske, opløsning Rituximab
NAME OF THE MEDICINAL PRODUCT MabThera 500 mg concentrate for solution for infusion Rituximab
Den gennemsnitlige Cmax efter den 4. infusion var 486 µg/ml (spændvidde 77,5 µg/ml - 996,6 µg/ml).
doses to 203 patients with NHL naive to MabThera, yielded a mean Cmax following the fourth infusion of 486 µg/mL (range, 77.5 to 996.6 µg/mL).
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/98/067/002
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/002
kemoterapi alene (p=0,0319, log-rank test) (tabel 2a).
The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p = 0.0319, log-rank test) (Table 2a).
Forkortelser: NA, ikke tilgængelig; ORR: samlet responsrate; CR: fuldstændigt respons; PR: partielt respons.
chemotherapy treatment; ORR: overall response rate; NR: not reached at time of clinical cut-off, OR: odds ratio.
Hos patienter der er blevet behandlet med MabThera, er der observeret udvikling af symptomer på tidligere eksisterende iskæmiske hjertelidelser,
In patients treated with MabThera, the occurrence of pre-existing ischemic cardiac conditions becoming symptomatic, such as angina pectoris, has been observed, as well as atrial fibrillation and flutter.
Der er totalt 6 behandlingsserier og hver serie har en varighed af 28 dage.
The total number of cycles is of 6.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/98/067/004
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/004
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/98/067/001
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/001
Der er efter markedsføring indberettet få tilfælde af hepatitis B-reaktivering, nogle med dødeligt udfald, blandt patienter med GPA eller MPA behandlet med MabThera.
A small number of cases of hepatitis-B reactivation, some with fatal outcome, have been reported in granulomatosis with polyangiitis and microscopic polyangiitis patients receiving MabThera in the postmarketing setting.
MabThera 100 mg, koncentrat til infusionsvæske, opløsning Rituximab
NAME OF THE MEDICINAL PRODUCT MabThera 100 mg concentrate for solution for infusion Rituximab
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/98/067/003
MARKETING AUTHORISATION NUMBER(S) EU/1/98/067/003
d)
PR
• muskelspasmer eller -rysten
• muscle twitches or shakiness
Bivirkninger rapporteret ved brug af MabThera subkutan formulering Risikoen for akutte administrationsrelaterede reaktioner i forbindelse med den subkutane formulering af MabThera er vurderet i 3 kliniske studier.
The risk of acute administration-related reactions associated with the subcutaneous formulation of MabThera was assessed in -three clinical trials: SparkThera and SABRINA (the two trials in NHL) and SAWYER the CLL trial.
Hyppigheden af infusionsrelaterede bivirkninger aftog væsentligt med de efterfølgende infusioner og var under 1 % efter den ottende behandlingsserie med MabThera.
The incidence of infusion-related symptoms decreased substantially with subsequent infusions and is <1% of patients by the eighth cycle of MabThera (containing) treatment.
Det skal du vide, før du begynder at få MabThera Sådan får du MabThera
What MabThera is and what it is used for What you need to know before you are given MabThera How MabThera is given
Ctrough (q2m)
(q2m) µg/mL
• hukommelsestab, koncentrationsbesvær, besær med at gå eller synstab - dette kan skyldes en meget sjælden, alvorlig hjerneinfektion, der i nogle tilfælde har været dødelig (progressiv multifokal leukoencefalopati eller PML).
serious brain infection, which has been fatal (Progressive Multifocal Leukoencephalopathy or
Patienter med stor tumorbyrde eller med et højt antal (≥ 25 x 109/l) cirkulerende maligne celler, som kan have øget risiko for især svært cytokinfrigivelsessyndrom, bør behandles med yderste forsigtighed.
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells,
Der er i meget sjældne tilfælde rapporteret toksisk epidermal nekrolyse (Lyells syndrom) og StevensJohnsons syndrom, nogle med dødelig udgang.
Toxic Epidermal Necrolysis (Lyell's syndrome) and Stevens-Johnson syndrome, some with fatal outcome, have been reported very rarely.
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter): væskeophobning i ansigtet og kroppen
Common side effects (may affect up to 1 in 10 people): • Infections such as bronchial tube inflammation (bronchitis)
• fodsvamp
PFSb
Follikulær non-Hodgkin-lymfom
Non-Hodgkin's lymphoma
Taxotere fik en markedsføringstilladelse med gyldighed i hele EU den 27. november 1995.
Taxotere received a marketing authorisation valid throughout the EU on 27 November 1995.
Andre oplysninger om Taxotere
Other information about Taxotere
Yderligere information om Taxotere findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/taxotere.
Further information on Taxotere can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/taxotere.
Som for alle lægemidler bliver data vedrørende brugen af Taxotere løbende overvåget.
As for all medicines, data on the use of Taxotere are continuously monitored.
Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Taxotere opvejer risiciene, og at det kan godkendes til anvendelse i EU.
The European Medicines Agency decided that Taxotere's benefits are greater than its risks and it can be authorised for use in the EU.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Taxotere?
What measures are being taken to ensure the safe and effective use of Taxotere?
Taxotere gives som infusion (drop) i en blodåre over en time hver tredje uge.
Taxotere is given as a 1-hour infusion (drip) into a vein every 3 weeks.
• ikke-småcellet lungekræft.
• non-small cell lung cancer.
En oversigt over Taxotere, og hvorfor det er godkendt i EU
An overview of Taxotere and why it is authorised in the EU
Tilføjelse af Taxotere til andre kræftbehandlinger var effektivt hos alle fem typer kræft.
Adding Taxotere to other anticancer treatments was effective in all five types of cancer.
I de fleste af disse studier blev Taxotere kombineret med andre kræftbehandlinger og sammenlignet med enten de lægemidler, som det anvendes i kombination med, eller med en kombination af forskellige behandlinger.
In most of these studies, Taxotere was combined with other cancer treatments and compared either with the medicines it is used in combination with or with a combination of different treatments.
Taxotere er et kræftlægemiddel, der anvendes til behandling af følgende kræfttyper:
Taxotere is a cancer medicine used to treat the following types of cancer:
De indberettede bivirkninger ved Taxotere vurderes omhyggeligt, og der træffes de nødvendige forholdsregler for at beskytte patienterne.
Side effects reported with Taxotere are carefully evaluated and any necessary action taken to protect patients.
Taxotere må ikke anvendes hos patienter med et neutrofiltal under 1.500 celler/mm3 eller alvorlige leverproblemer.
Taxotere must not be used in patients who have a neutrophil count of less than 1,500 cells/mm3 or who have severe problems with their liver.
Virkningen blev hovedsagelig bedømt på antallet af patienter, hvis kræft responderede på behandlingen, hvor længe patienterne levede uden en forværring af deres sygdom, og hvor længe patienterne overlevede.
The main measures of effectiveness were the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived.
Hvorfor er Taxotere godkendt i EU?
Why is Taxotere authorised in the EU?
Hvis du ønsker mere information om anvendelsen af Taxotere, kan du læse indlægssedlen eller kontakte lægen eller apotekspersonalet.
For more information about using Taxotere, see the package leaflet or contact your doctor or pharmacist.
Dosis, behandlingsvarighed og anvendelse sammen med andre lægemidler afhænger af, hvilken kræftform der behandles, samt patientens vægt og højde.
The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated and the patient's weight and height.
Hvad er Taxotere, og hvad anvendes det til?
What is Taxotere and what is it used for?
Taxotere er undersøgt hos over 4.000 patienter med brystkræft, ca. 2.000 patienter med ikkesmåcellet lungekræft, ca. 2.700 patienter med prostatakræft, 457 patienter med adenokarcinom i maven og 897 patienter med kræft i hoved- og halsregionen.
Taxotere has been studied in over 4,000 breast-cancer patients, around 2,000 non-small-cell-lungcancer patients, around 2,700 prostate cancer patients, 457 gastric adenocarcinoma patients and 897 head- and neck-cancer patients.
Taxotere anvendes sammen med cisplatin og fluorouracil.
Taxotere is used with cisplatin and fluorouracil.
Disse bivirkninger kan være mere alvorlige, når Taxotere anvendes sammen med andre kræftmidler.
These side effects may be more severe when Taxotere is used with other cancer medicines.
Taxotere indeholder det aktive stof docetaxel.
Taxotere contains the active substance docetaxel.
Taxotere kan bruges alene, når andre lægemidler har været uden virkning.
Taxotere can be used on its own after other treatments have failed.
Det aktive stof i Taxotere, docetaxel, tilhører en gruppe kræftmidler, der kaldes taxaner.
The active substance in Taxotere, docetaxel, belongs to the group of cancer medicines known as taxanes.
Da docetaxel indvirker på cellernes deling, påvirker det også andre celler end kræftcellerne, f.eks. blodcellerne, hvilket kan medføre bivirkninger.
Because docetaxel works on dividing cells, it also affects affects non-cancer cells such as blood cells, which can cause side effects.
Hvilke risici er der forbundet med Taxotere?
What are the risks associated with Taxotere?
De hyppigste bivirkninger ved Taxotere (som forekommer hos mere end 1 ud af 10 patienter) er neutropeni (lavt antal neutrofiler, der er hvide blodlegemer, som bekæmper infektioner), blodmangel (lavt antal røde blodlegemer), betændelse i mundslimhinden, diarré, kvalme, opkastning, hårtab og svaghed.
The most common side effects with Taxotere (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, white blood cells that fight infection), anaemia (low red blood cell counts), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss) and asthenia (weakness).
Docetaxel blokerer cellernes evne til at nedbryde det indvendige 'celleskelet' og dermed deres evne til at dele sig.
Docetaxel blocks the ability of cells to break down the internal ‘skeleton' that allows them to divide.
Taxotere anvendes sammen med cisplatin og fluorouracil (andre lægemidler mod kræft)
Taxotere is used with cisplatin and fluorouracil (other cancer medicines);
• prostatakræft, når kræften har spredt sig til andre dele af kroppen.
• prostate cancer, when the cancer has spread to other parts of the body (metastatic).
• gastrisk adenokarcinom (en form for mavekræft), der har spredt sig hos patienter, der endnu ikke har fået nogen behandling mod deres kræft.
• gastric adenocarcinoma (a stomach cancer) that has spread in patients who have not received any treatment for their cancer.